The race to find a cure for COVID-19 began on January 10, 2020 when the Chinese government released the genetic sequence of the virus – SARS-CoV-2 – responsible for the global pandemic of an extremely spreadable and potentially fatal disease. Researchers around the world began to build bits of the virus in their labs to develop therapies, with the aim of making us immune. Join us to learn how researchers at Nationwide Children’s Hospital developed a method for generating large numbers of clinical-grade Natural Killer (NK) cells for cancer therapy which has the potential to augment the innate immunity of high-risk patients with mild or moderate COVID-19 disease and to prevent progression to severe COVID-19 disease.
Related Posts
